MAP2K7 and melanoma: Class 1 BRAF mutant cancers are targetable with combinations of BRAF, MEK, and EGFR targeted therapies for advanced-stage melanoma, non-small cell lung cancer (NSCLC), and colorectal cancer (CRC) [7,8,9,10,11].